<DOC>
	<DOCNO>NCT00123110</DOCNO>
	<brief_summary>The purpose research study determine relationship insulin resistance ( IR ) testosterone ( T ) exist woman already go menopause .</brief_summary>
	<brief_title>Insulin Resistance Testosterone Women</brief_title>
	<detailed_description>This study test central hypothesis insulin resistance ( IR ) increase androgen ( male sex hormone ) production postmenopausal woman . Participation include five visit , lasting average 2.5 hour , period 13-20 week . At screen visit , participant 's medical history , current use medication dietary supplement , social habit record . This information review subsequent visit ; participant ask maintain current diet physical activity level throughout study . A brief physical exam perform , blood drawn . At 2nd ( baseline ) visit , patient undergo euglycemic-hyperinsulinemic clamp ( procedure measure insulin sensitivity continuous intravenous infusion insulin , variable infusion glucose ) . Blood sample draw throughout procedure . At completion , insulin infusion stop , participant feed , glucose infusion continue least 15 minute ensure stability blood glucose concentration . After procedure , participant randomize receive either metformin plus leuprolide placebo , leuprolide plus metformin placebo , metformin placebo plus leuprolide placebo . The leuprolide leuprolide placebo administer injection nurse . The metformin metformin placebo dispense participant form pill , instruction titrate dose . Participants contact telephone weekly titration period assess drug tolerability adverse event ( AEs ) . Participants maintain maximum tolerated dose duration study intervention period . Participants return every 4 week follow-up . Blood drawn , nurse administer leuprolide leuprolide placebo injection , metformin metformin placebo dispense . At final visit ( week 12 ) , participant undergo brief physical exam , undergo final euglycemic-hyperinsulinemic clamp .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Postmenopausal woman age 5079 year absence menses 12 month ; woman 5054 year , FSH &gt; 30 mIU/mL confirm postmenopausal status At least one intact ovary Free testosterone fast insulin level within require study parameter Willing comply studyrelated procedure Capable give informed consent History cancer require treatment within past 5 year ( exception may make investigator ) Hospitalization treatment vascular disease past 6 month Uncontrolled hypertension Hospitalization chronic obstructive pulmonary disease asthma past 3 month Use continuous oxygen home Surgery last 30 day Positive HIV Abnormal blood test ( hemoglobin , fast triglyceride , fast glucose , creatinine , liver function ) History diabetes mellitus use antihyperglycemic medication past 3 month Disease associate disorder glucose metabolism ( Cushing 's disease , acromegaly , pheochromocytoma surgically cure , chronic pancreatitis ) History chronic renal insufficiency Intravenous ( IV ) contrast study iodinate material plan 12 week intervention period postpone accord participant 's primary care provider Acute chronic metabolic acidosis History liver disease Congestive heart failure History androgensecreting tumor Hormone replacement therapy antiandrogen use past 6 month Use DHEA androgencontaining product past 6 month Corticosteroid use , topical , ophthalmic , intraarticular , inhaled preparation , past 3 month Undiagnosed current vaginal bleeding Excessive alcohol intake , either acute chronic ; current illicit substance abuse Participation investigational drug study within 6 week prior screen visit Serious unstable medical psychological condition , opinion investigator , would compromise patient 's safety successful participation study</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>